Search
Results
showing 1-10 of 2325
EXPrESSIVE Phase III Program Countries of Alimatravir
October 2026
Seventeen countries are hosting sites for the Phase III efficacy trials of a monthly PrEP pill, called MK-8527, now known as alimatravir, being developed by Merck (also known as MSD outside of the US and Canada). Merck announced the launch of the Phase III trials at IAS 2025 in Kigali. Alimatravir (AMI) was found to be safe and well-tolerated in Phase II clinical trials.
No Time to Lose: Reaching At Least Three Million with LEN for PrEP by 2027
October 2026
AVAC and Access Bridge today issued a global call to action and new publication urging governments, donors, manufacturers, implementers, and advocates to work toward a bold but achievable goal: reaching at least three million people with injectable lenacapavir (LEN) for HIV prevention by the end of 2027. This new, more ambitious target will drive affordability, build a sustainable PrEP market, and accelerate impact.
Source of Lenacapavir for PrEP Supply to Early Adopter Countries
October 2026
The Global Fund, with support from CIFF, and PEPFAR have jointly committed to reaching up to two million people with injectable lenacapavir for PrEP over three years. Supply of LEN began arriving in countries in late 2025 with service delivery starting in early 2026.
Now What with Injectable LEN for PrEP?
October 2026
Since results of the PURPOSE efficacy trials were announced in 2024, injectable lenacapavir for PrEP (LEN) has generated enormous excitement and opportunity – and frustration. By the end of 2024, Gilead Sciences provided six voluntary licenses to generic manufacturers and submitted multiple regulatory filings, and the Global Fund and PEPFAR committed to an ambition to reach two million people over three years, pending regulatory approvals and WHO guidelines. It seemed like bold ambition – and it was, compared to the previous launches of oral PrEP, vaginal ring and CAB.
But this ambition was always defined as a floor, not a ceiling. In April 2026, the collaboration increased the goal to reach three million people over three years with LEN for PrEP. In July 2025, AVAC published a first edition of Now What with Injectable LEN for PrEP, outlining priorities to ensure introduction moved swiftly. Now, in this update, AVAC is calling for a new minimum floor: reach three million in two years (2026-2027). No less and no slower, with a push for more and faster.
Global Health Watch: World Health Summit highlights, UN pandemic declaration, Guinea-Bissau vaccine trial, NIH peer-review changes
October 2026
Challenges and scientific progress took center stage at the World Health Summit in Berlin, the UN adopted a new pandemic preparedness declaration, concerns continue over the proposed US-funded hepatitis B vaccine trial in Guinea-Bissau, and proposed changes to NIH’s scientific peer-review process raise new questions about transparency and political influence over research funding.
Injectable PrEP Regulatory Approvals
October 2026
This graphic tracks regulatory approvals for injectable cabotegravir and lenacapavir for PrEP as of October 2026.
Global Health Watch: NIH Orders Pause on HIV Trials, Zimbabwe + Zambia Health MoUs, WHO + Global Fund leadership, Foreign Assistance Funds
October 2026
The US National Institutes of Health (NIH) said its HIV clinical trial networks should “temporarily hold off on launching new studies that had not yet enrolled participants and that would not be complete by November 30, 2027, when their current funding is set to expire.” This potentially devastating development comes as new questions emerge about how billions in US foreign assistance funding were spent, and details on the impacts of an end of US health assistance to Zimbabwe emerge. Also, a new candidate for WHO leadership and growing civil society calls to protect UNAIDS.
The Latest Resources from AVAC: The Power of Coalition Advocacy
October 2026
Advocacy has always been the heartbeat of progress in the fight against HIV/AIDS. Now, more than ever, it is especially needed to ensure that innovation translates into real choices, equitable access and meaningful impact. In this issue, we highlight the power of coalition advocacy – from advocates working in partnership to shape research agendas and oppose policies that threaten progress, to ensuring communities have a voice in AI development and use, to the lessons learned from sustained, coalition-based advocacy that will shape what comes next.
Advocates Lead at AIDS 2026: Moving from a seat at the table to the head of the table
October 2026
The power and leadership of advocates were on full display at AIDS 2026. Following global funding cuts and concerns about de-prioritization of communities and civil society, advocates brought evidence of their impact and the value of continued investment in communities to Rio. On topics ranging from HIV prevention access to the future of artificial intelligence in HIV programs, advocates were driving conference discussions to ensure the community agenda was seen, heard and acted upon.
showing 1-10 of 2325